[A23-17] Dolutegravir/abacavir/lamivudine (HIV infection in children) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2023
Project no.:
A23-17
Commission:
Commission awarded on 01.03.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Children with HIV-1 infection
Result of dossier assessment:
- Treatment-naive children aged 2 to < 6 years: added benefit not proven
- Treatment-naive children aged 6 to < 12 years: added benefit not proven
- Treatment-experienced children aged 2 to < 12 years: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A14-34 | Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |